Cargando…

Epac activation inhibits IL-6-induced cardiac myocyte dysfunction

Pro-inflammatory cytokines are released in septic shock and impair cardiac function via the Jak-STAT pathway. It is well known that sympathetic and thus catecholamine signaling is activated thereafter to compensate for cardiac dysfunction. The mechanism of such compensation by catecholamine signalin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Huiling, Fujita, Takayuki, Jin, Meihua, Kurotani, Reiko, Hidaka, Yuko, Cai, Wenqian, Suita, Kenji, Prajapati, Rajesh, Liang, Chen, Ohnuki, Yoshiki, Mototani, Yasumasa, Umemura, Masanari, Yokoyama, Utako, Sato, Motohiko, Okumura, Satoshi, Ishikawa, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353818/
https://www.ncbi.nlm.nih.gov/pubmed/27995459
http://dx.doi.org/10.1007/s12576-016-0509-5
_version_ 1783391034328219648
author Jin, Huiling
Fujita, Takayuki
Jin, Meihua
Kurotani, Reiko
Hidaka, Yuko
Cai, Wenqian
Suita, Kenji
Prajapati, Rajesh
Liang, Chen
Ohnuki, Yoshiki
Mototani, Yasumasa
Umemura, Masanari
Yokoyama, Utako
Sato, Motohiko
Okumura, Satoshi
Ishikawa, Yoshihiro
author_facet Jin, Huiling
Fujita, Takayuki
Jin, Meihua
Kurotani, Reiko
Hidaka, Yuko
Cai, Wenqian
Suita, Kenji
Prajapati, Rajesh
Liang, Chen
Ohnuki, Yoshiki
Mototani, Yasumasa
Umemura, Masanari
Yokoyama, Utako
Sato, Motohiko
Okumura, Satoshi
Ishikawa, Yoshihiro
author_sort Jin, Huiling
collection PubMed
description Pro-inflammatory cytokines are released in septic shock and impair cardiac function via the Jak-STAT pathway. It is well known that sympathetic and thus catecholamine signaling is activated thereafter to compensate for cardiac dysfunction. The mechanism of such compensation by catecholamine signaling has been traditionally understood to be cyclic AMP-dependent protein kinase (PKA)-mediated enforcement of cardiac contractility. We hypothesized that the exchange protein activated by cAMP (Epac), a newly identified target of cAMP signaling that functions independently of PKA, also plays a key role in this mechanism. In cultured cardiac myocytes, activation of Epac attenuated the inhibitory effect of interleukin-6 on the increase of intracellular Ca(2+) concentration and contractility in response to isoproterenol, most likely through inhibition of the Jak-STAT pathway via SOCS3, with subsequent changes in inducible nitric oxide synthase expression. These findings suggest a new role of catecholamine signaling in compensating for cardiac dysfunction in heart failure. Epac and its downstream pathway may be a novel target for treating cardiac dysfunction in endotoxemia.
format Online
Article
Text
id pubmed-6353818
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-63538182019-02-21 Epac activation inhibits IL-6-induced cardiac myocyte dysfunction Jin, Huiling Fujita, Takayuki Jin, Meihua Kurotani, Reiko Hidaka, Yuko Cai, Wenqian Suita, Kenji Prajapati, Rajesh Liang, Chen Ohnuki, Yoshiki Mototani, Yasumasa Umemura, Masanari Yokoyama, Utako Sato, Motohiko Okumura, Satoshi Ishikawa, Yoshihiro J Physiol Sci Original Paper Pro-inflammatory cytokines are released in septic shock and impair cardiac function via the Jak-STAT pathway. It is well known that sympathetic and thus catecholamine signaling is activated thereafter to compensate for cardiac dysfunction. The mechanism of such compensation by catecholamine signaling has been traditionally understood to be cyclic AMP-dependent protein kinase (PKA)-mediated enforcement of cardiac contractility. We hypothesized that the exchange protein activated by cAMP (Epac), a newly identified target of cAMP signaling that functions independently of PKA, also plays a key role in this mechanism. In cultured cardiac myocytes, activation of Epac attenuated the inhibitory effect of interleukin-6 on the increase of intracellular Ca(2+) concentration and contractility in response to isoproterenol, most likely through inhibition of the Jak-STAT pathway via SOCS3, with subsequent changes in inducible nitric oxide synthase expression. These findings suggest a new role of catecholamine signaling in compensating for cardiac dysfunction in heart failure. Epac and its downstream pathway may be a novel target for treating cardiac dysfunction in endotoxemia. Springer Japan 2016-12-19 2018 /pmc/articles/PMC6353818/ /pubmed/27995459 http://dx.doi.org/10.1007/s12576-016-0509-5 Text en © The Author(s) 2016, corrected publication 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
spellingShingle Original Paper
Jin, Huiling
Fujita, Takayuki
Jin, Meihua
Kurotani, Reiko
Hidaka, Yuko
Cai, Wenqian
Suita, Kenji
Prajapati, Rajesh
Liang, Chen
Ohnuki, Yoshiki
Mototani, Yasumasa
Umemura, Masanari
Yokoyama, Utako
Sato, Motohiko
Okumura, Satoshi
Ishikawa, Yoshihiro
Epac activation inhibits IL-6-induced cardiac myocyte dysfunction
title Epac activation inhibits IL-6-induced cardiac myocyte dysfunction
title_full Epac activation inhibits IL-6-induced cardiac myocyte dysfunction
title_fullStr Epac activation inhibits IL-6-induced cardiac myocyte dysfunction
title_full_unstemmed Epac activation inhibits IL-6-induced cardiac myocyte dysfunction
title_short Epac activation inhibits IL-6-induced cardiac myocyte dysfunction
title_sort epac activation inhibits il-6-induced cardiac myocyte dysfunction
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353818/
https://www.ncbi.nlm.nih.gov/pubmed/27995459
http://dx.doi.org/10.1007/s12576-016-0509-5
work_keys_str_mv AT jinhuiling epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT fujitatakayuki epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT jinmeihua epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT kurotanireiko epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT hidakayuko epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT caiwenqian epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT suitakenji epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT prajapatirajesh epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT liangchen epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT ohnukiyoshiki epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT mototaniyasumasa epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT umemuramasanari epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT yokoyamautako epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT satomotohiko epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT okumurasatoshi epacactivationinhibitsil6inducedcardiacmyocytedysfunction
AT ishikawayoshihiro epacactivationinhibitsil6inducedcardiacmyocytedysfunction